% | $
Quotes you view appear here for quick access.

Myrexis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • jacosa jacosa Oct 4, 2011 10:28 AM Flag

    A new high priced CFO?

    I listened to the latest presentation (Q&A not webccast). It sure sounded like the new business plan is to license the entire pipeline and get out of the research business. That would make the CFO a key player.

    I'd be pitching Azixa mostly to Roche; a combination with Avastin looks extremely attractive in principle (but very expensive to develop). Of the active programs, I'd be pushing hardest to license the metabolism inhibitor: the other two have the potential to become a lot more valuable than they presently are with a little more research.

    This train wreck makes me appreciate Incyte a lot more. Their stock is way off, but starting from the same sort of discovery program, and with a lot less seed money, they're getting two drugs to market [almost] for sure. The key seems to be that their technical leader is almost as good a money guy as the real money guys.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.0808-0.0073(-8.25%)Feb 8 9:30 AMEST